Pro-Dex, Inc. (PDEX) Stock Price & Analysis
Pro-Dex, Inc. (PDEX) — MoonshotScore 87/100 (Exceptional band), calculated Nov 18, 2026. Price $63.49 (-0.70%), as of the Nov 19, 2026 trading session; market cap $203M.
Educational signal · not a buy or sell recommendation · How to read this
Pro-Dex, Inc. · PDEX · NASDAQ
Pro-Dex, Inc. is a leading manufacturer of powered surgical instruments, primarily serving the orthopedic, thoracic, and craniomaxillofacial markets.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Pro-Dex (PDEX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $19M (Q1 FY2026, quarter ended Sep 2025)
- EPS beat 7 of the last 8 reports
- Altman Z 7.62 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $63.49 | |
| Change on the day | -0.70% | |
| Market capitalisation | $203M | — |
| Price / earnings (trailing) | 16.56 | |
| Shares traded on the day | 36.6K |
Price & events
Other perspectives
Council score for Pro-Dex (PDEX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Pro-Dex (PDEX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pro-Dex, Inc. (PDEX) is listed on NASDAQ. It employs 201 people. In Q1 FY2026 it reported revenue of $19M and net income of $5M. The market values it at $203M.
What do the latest results show for Pro-Dex (PDEX)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $19M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $19M | $5M | $1.40 (diluted) |
| Q2 FY2026 | $19M | $2M | $0.66 (diluted) |
| Q3 FY2026 | $20M | $4M | $1.20 (diluted) |
| Q4 FY2026 | $20M | $3M | $0.87 (diluted) |
What are the financial strengths and risks for Pro-Dex (PDEX)?
Short answer · as of
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 7.62 · Piotroski F 6. Trailing ratios: ROE 26.2% · ROA 15.7% · current ratio 4.19 · earnings yield 5.8% · free-cash-flow yield 5.2%.
How does Pro-Dex compare with its peers?
Short answer
Pro-Dex's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Pro-Dex (PDEX) — this page | $63.49 | $203M | 87 |
| $70.96 Nov 19, 2026 | $202M | 87 5-pillar Nov 18, 2026 | |
| $14.06 Nov 19, 2026 | $282M | 85 5-pillar Nov 18, 2026 | |
| $267.14 Nov 19, 2026 | $643B | 83 5-pillar Nov 18, 2026 | |
| $100.61 Nov 19, 2026 | $129B | 81 5-pillar Nov 18, 2026 | |
| $318.15 Nov 18, 2026 | $121B | 80 5-pillar Nov 18, 2026 | |
| $101.47 Nov 19, 2026 | $19.2B | 79 5-pillar Nov 18, 2026 | |
| $42.99 Nov 19, 2026 | $62.3B | 77 5-pillar Nov 18, 2026 | |
| $10.05 Nov 19, 2026 | $350M | 65 5-pillar Nov 18, 2026 | |
| $3.65 Nov 19, 2026 | $160M | 55 5-pillar Nov 18, 2026 | |
| $32.67 Nov 19, 2026 | $300M | 39 5-pillar Nov 18, 2026 | |
| $10.76 Nov 19, 2026 | $453M | 37 5-pillar Nov 18, 2026 | |
| $3.61 Nov 19, 2026 | $249M | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 11, 2026
- Transactions
- 20
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 13
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PDEX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PDEX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Pro-Dex (PDEX)?
Pro-Dex Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the PDEX research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PDEX?
PDEX carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PDEX a good stock to buy?
Stock Expert AI does not rate PDEX buy, sell or hold. Pro-Dex, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PDEX stock price today?
The last price recorded for Pro-Dex, Inc. (PDEX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for PDEX?
Pro-Dex, Inc. faces several risks that could impact its operations and market position. These include potential regulatory changes that may affect product approvals, intense competition from larger medical device manufacturers, and economic fluctuations that could reduce healthcare spending.
What are the key factors to evaluate for PDEX?
Pro-Dex, Inc. (PDEX) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does PDEX data refresh on this page?
PDEX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PDEX's recent stock price performance?
Pro-Dex, Inc. (PDEX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand with a strong reputation in the medical instruments sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PDEX overvalued or undervalued right now?
The trailing P/E of Pro-Dex, Inc. (PDEX) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PDEX?
Fractional-share availability for Pro-Dex, Inc. (PDEX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 10 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com